Earnings Ahead

KPTI - Karyopharm Therapeutics

3.18 0.05 1.6

  1. Home
  2. Healthcare
  3. KPTI
Karyopharm Therapeutics

Karyopharm Therapeutics

About

Profile

Headquarters

Newton Centre, Newton, Massachusetts, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

KPTI



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Karyopharm Therapeutics GAAP EPS of -$0.45 beats by $0.10, revenue of $36.1M beats by $1.27M
  • Karyopharm Therapeutics Q3 2022 Earnings Preview
  • Karyopharm granted orphan drug status by EC for Xpovio for myelofibrosis
  • Karyopharm Therapeutics GAAP EPS of -$0.62 misses by $0.01, revenue of $39.68M beats by $3.72M
  • Karyopharm Therapeutics Q2 2022 Earnings Preview
  • Karyopharm wins full EU approval for multiple myeloma therapy
  • Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU
  • Biogen terminates 2018 asset purchase agreement with Karyopharm Therapeutics
  • Karyopharm director sells ~$3.4M in company shares
  • Bluebird Bio, Clovis Oncology, Chimerix drop as Truist flags liquidity concerns
  • Karyopharm wins FDA’s Orphan Drug status for leading asset in myelofibrosis
  • Karyopharm begins dosing in late-stage study of selinexor combo therapy for multiple myeloma
  • EU drug regulator panel recommends expanding indication for Karyopharm's Nexpovio
  • Karyopharm Therapeutics GAAP EPS of -$0.53 beats by $0.14, revenue of $47.67M beats by $13.26M
  • Karyopharm Therapeutics Q1 2022 Earnings Preview
  • Karyopharm sinks on setback for U.S. label expansion of cancer therapy
  • Karyopharm slips as medical chief steps down
  • Karyopharm spikes on cancelation of presentation at SVB Leerink conference
  • Karyopharm falls 13% following late-stage results on selinexor for endometrial cancer
  • Karyopharm TherapeuticsEPS of $0.46, revenue of $126.2M beats by $94.28M
Date Price Open High Low Vol ER
Nov 21 4.71 4.97
5.01
4.61
1.6M
Nov 22 4.82 4.72
4.83
4.56
952K
Nov 23 4.91 4.81
4.998
4.8
1.1M
Nov 25 4.94 4.89
4.96
4.8
403K
Nov 28 4.89 4.86
4.98
4.8
1.0M
 
Nov 29 5.07 4.94
5.129
4.9
1.2M
Nov 30 5.29 5.11
5.345
4.99
1.5M
Dec 01 4.98 5.28
5.32
4.915
954K
Dec 02 5.15 5
5.17
4.83
846K